Investigational malaria vaccine gives strong, lasting protection
(NIH/National Institute of Allergy and Infectious Diseases) Two U.S. Phase 1 clinical trials of a novel candidate malaria vaccine have found that the regimen conferred unprecedentedly high levels of durable protection when volunteers were later exposed to disease-causing malaria parasites. The vaccine combines live parasites with either of two widely used antimalarial drugs -- an approach termed chemoprophylaxis vaccination. A Phase 2 clinical trial of the vaccine is now underway in Mali, a malaria-endemic country.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
More News: Allergy | Allergy & Immunology | Clinical Trials | Endemics | Infectious Diseases | Malaria | Malaria Vaccine | Mali Health | Parasitic Diseases | Parasitology | Vaccines